NMTC (NeuroOne Medical Technologies) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is NeuroOne Medical Technologies LT-Debt-to-Total-Asset?

NeuroOne Medical Technologies NMTC -0.66% 39 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates NMTC with a GF Score™ of 39/100 and a GF Value™ of $6.60 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NeuroOne Medical Technologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

NeuroOne Medical Technologies's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.01). It may suggest that NeuroOne Medical Technologies is progressively becoming less dependent on debt to grow their business.

NeuroOne Medical Technologies (NAS:NMTC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NeuroOne Medical Technologies LT-Debt-to-Total-Asset Related Terms

NeuroOne Medical Technologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies LT-Debt-to-Total-Asset Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.01

0.04

0.01

NeuroOne Medical Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.02	0.01	0.01	0.01

39GF Score

NeuroOne Medical Technologies Corp NMTC

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NeuroOne Medical Technologies LT-Debt-to-Total-Asset Calculation

NeuroOne Medical Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )	/	Total Assets (A: Sep. 2025 )
	=	0.143	/	10.786
	=	0.01

NeuroOne Medical Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.092	/	7.865
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

NeuroOne Medical Technologies (NMTC) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on NeuroOne Medical Technologies and its competitors.

Is NeuroOne Medical Technologies' LT-Debt-to-Total-Asset too high?

NeuroOne Medical Technologies' current LT-Debt-to-Total-Asset is 0.01. Overall, NeuroOne Medical Technologies has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does NeuroOne Medical Technologies' LT-Debt-to-Total-Asset compare to RDGL and TANAF?

NeuroOne Medical Technologies' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NeuroOne Medical Technologies stock overvalued right now?

Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.60, compared to a current price of $3.01 — trading 54.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. NeuroOne Medical Technologies' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.01 is trading 54.4% below its estimated GF Value™ of $6.60. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $6.60 vs. price of $3.01 (54.4% below fair value)
GF Score™: 39/100 with 3 warning signs

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroOne Medical Technologies Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies RDGL TANAF MODD PETV ARAY CTSO NSPR TELA BDMD GTHP ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344

Website https://www.n1mtc.com

NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

39GF Score

Get the complete analysis for NMTC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.01

Price

$6.60

GF Value

View NMTC Analysis

See LT-Debt-to-Total-Asset data for all stocks →